Core Message - Amarin Corporation emphasizes the urgent need to utilize existing, proven therapies to significantly reduce cardiovascular disease (CVD) events in the U.S. during American Heart Month [1][7]. Group 1: Current State of Cardiovascular Disease - CVD remains the leading cause of death in the U.S., affecting nearly half of the adult population, with 130.6 million adults (48.9%) living with some form of CVD as of 2023 [2]. - Despite available treatments, millions of high-risk patients remain untreated or undertreated, highlighting a significant gap between evidence and practice [4][9]. Group 2: Available Therapies and Their Impact - Guideline-supported therapies such as statins, ezetimibe, PCSK9 inhibitors, and icosapent ethyl have a proven history of reducing cardiovascular events [3][5]. - High-risk patients often fail to achieve LDL-C targets, with cumulative CV event rates reaching approximately 40% over 10 years among those treated with statins [9]. Group 3: Call to Action - Amarin calls for the cardiovascular community to recommit to data-driven care, ensuring that patients receive evidence-based treatments that are already available [7][11]. - The company urges stakeholders to review current practices, reassess therapies that do not demonstrate event reduction, and refocus on therapies backed by rigorous outcomes data [10][11]. Group 4: Future Innovations - While future innovations in cardiovascular treatments are promising, they are years away from delivering proven clinical outcomes, making immediate implementation of existing therapies critical [5][6].